Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 - Ozkaynak, M. Fevzi; Gilman, Andrew L.; London, Wendy B.; Naranjo, Arlene; Diccianni, Mitchell B.; Tenney, Sheena C.; Smith, Malcolm; Messer, Karen S.; Seeger, Robert; Reynolds, C. Patrick; Smith, L. Mary; Shulkin, Barry L.; et al. (Frontiers in Immunology, 2018)